In 2023, Switzerland led global nervous system medicine sales per capita, followed by Norway, Spain, and Luxembourg. Of significance, Estonia's sales surged by 4.43%, the highest growth rate among the countries listed, while Ireland saw the steepest decline at -3.73%. Other countries like Australia, Italy, and Switzerland experienced modest growth, whereas Spain and Luxembourg faced minor decreases. These variations highlight the diverse market dynamics across countries.
Future trends to monitor include advancements in medical research and development, healthcare policy changes, and demographic shifts, which may significantly influence nervous system medicine sales globally. Further technological advancements and increased healthcare access could drive per capita consumption up.
Top countries in Nervous System Medicine Sales by Country
| # | 8 Countries | US Dollars Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Switzerland | 154.3 | 2023 | +3% | +0.97% | View data |
| 2 | 2 Norway | 112.9 | 2023 | +0.27% | +2.5% | View data |
| 3 | 3 Spain | 84.7 | 2023 | +2.79% | -0.33% | View data |
| 4 | 4 Luxembourg | 63.8 | 2023 | -1.69% | -1.55% | View data |
| 5 | 5 Australia | 62.5 | 2023 | +1.46% | +1.44% | View data |
| 6 | 6 Ireland | 57.8 | 2023 | -5.56% | -3.73% | View data |
| 7 | 7 Italy | 35.6 | 2023 | +0.28% | +0.28% | View data |
| 8 | 8 Estonia | 31.3 | 2023 | +1.95% | +4.43% | View data |
